Given its substrate targets (e.g. BAF155 and RUNX1) and gene targets (e.g. BMI-1 and ID2), CARM1 and phospho-CARM1 appear to play a pivotal role in hematologic malignancies with the JAK2-V617F mutation, and likely in other settings as well. Here, JAK2 is linked to hematologic disorder.